Fusion Protein Or Fusion Polypeptide (i.e., Expression Product Of Gene Fusion) Patents (Class 424/192.1)
  • Patent number: 11219683
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: January 11, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE M{circumflex over (D)}DICALE (INSERM), UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BAYLOR RESEARCH INSTITUTE
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 11155832
    Abstract: The invention provides adenoviral vectors and compositions for the highly efficient transduction of T cells.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 26, 2021
    Assignee: GenVec, Inc.
    Inventors: Sebastien M. Maloveste, Damodar Ettyreddy, Douglas E. Brough
  • Patent number: 11154606
    Abstract: In certain embodiments, the present invention provides a poultry vaccine comprising an antigenic protein comprising a PlcC protein unit that is operably linked to a peptide linker that is operably linked to a NetB protein unit, where the vaccine is effective in stimulating a protective cellular and/or humoral immune response to C. perfringens. Methods are also provided for making the vaccine and for vaccinating poultry by administering such a vaccine.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: October 26, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Kenneth Roland, Andrew Diamos, Hugh Mason
  • Patent number: 11141492
    Abstract: Provided herein, inter alia, are compositions and kits comprising a bacterial cell and a tumor penetrating agent. Also provided are methods of treating cancer in a subject including the step of administering to the subject an effective amount of a bacterial cell and a tumor penetrating agent. Provided are methods of stimulating an immune system in a subject. The methods include administering to the subject an effective amount of a bacterial cell and a tumor penetrating agent. Also provided are methods of enhancing delivery of an anti-cancer agent to a tumor cell including the step of contacting the tumor cell with a bacterial cell, a tumor penetrating agent and an anti-cancer agent.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: October 12, 2021
    Assignee: CITY OF HOPE
    Inventors: Don J. Diamond, Edwin Manuel
  • Patent number: 11117972
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: September 14, 2021
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Hata, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Patent number: 11111310
    Abstract: Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: September 7, 2021
    Assignee: Cell Design Labs, Inc.
    Inventors: Stephen Santoro, Scott Coyle, Levi Rupp, Peter Emtage
  • Patent number: 11098379
    Abstract: The present disclosure relates to a composition for detecting a potato virus Y including an M13KO7 bacteriophage and a kit including the same. Since the M13KO7 bacteriophage of the present disclosure may be easily produced using E. coli and is a large aggregate of proteins, the M13KO7 bacteriophage is more stable than antibodies even when exposed to external physical or chemical factors. Therefore, the composition of the present disclosure has an effect of diagnosing only the PVY specifically and accurately and may be usefully used in related industries.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: August 24, 2021
    Assignees: Research & Business Foundation Sungkyunkwan University, Republic of Korea (Management: Rural Development Administration)
    Inventors: Suk-Chan Lee, Sang-Ho Cho, Young-Gyu Lee
  • Patent number: 11078240
    Abstract: A fusion protein comprising a first recombinant viral coat protein, a second recombinant viral coat protein and a first linkage peptide is provided. The first recombinant viral coat protein is linked to N-terminus of the first linkage peptide. The second recombinant viral coat protein is linked to C-terminus of the first linkage peptide. The first and second recombinant viral coat proteins are derived from the coat protein (CP) of alfalfa mosaic virus (AIMV). The fusion protein may form a virus like particle (VLP). Where the fusion protein further comprises a target protein, the target protein may be displayed on the surface of the VLP. Also provided are methods for producing the fusion protein and the VLP as well as the uses of the fusion protein and/or the VLP.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 3, 2021
    Assignee: Fraunhofer USA Inc.
    Inventors: Stephen Tottey, Konstantin Musiychuk
  • Patent number: 11041157
    Abstract: Provided in the present invention are a Slit2D2-HAS fusion protein and the use thereof against tumours. The fusion protein can significantly inhibit the migration of tumour cells. Also provided in the present invention are a pharmaceutical composition comprising the fusion protein and a method for preparing the fusion protein.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: June 22, 2021
    Inventor: Huashun Li
  • Patent number: 10954502
    Abstract: Compositions and methods for regulating the blood coagulation pathway are disclosed. More particularly, the present disclosure relates to thrombin-thrombomodulin fusion proteins, vectors, host cells and methods for preparing the thrombin-thrombomodulin fusion proteins. The present disclosure further relates to methods for measuring protein C in plasma and kits for measuring protein C in plasma.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 23, 2021
    Assignee: Saint Louis University
    Inventors: Sergio Barranco-Medina, Nicola Pozzi, Enrico Di Cera
  • Patent number: 10906935
    Abstract: Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: February 2, 2021
    Assignees: United Therapeutics Corporation, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: David Meh, Timothy Atolagbe, G. Mark Farquharson, Samir Shaban, Mary Koleck, George Mitra
  • Patent number: 10881684
    Abstract: Disclosed herein are artificial Invaplexes comprising deacylated lipopolysaccharides and methods of making and using thereof.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: January 5, 2021
    Assignee: The United States Government as represented by the Secretary of the Army
    Inventors: Robert W. Kaminski, Kevin R. Turbyfill, Edwin V. Oaks, Kristen Clarkson
  • Patent number: 10869939
    Abstract: The present invention relates to new molecular design that allows micelles to report their activation and disassembly by an enzymatic trigger. The molecular design is based on introduction of a labeling moiety selected from a fluorescent dye, a dark quencher, combinations of dyes or dyes/quenchers, and a fluorinated moiety (a 19F-magenetic resonance (MR) probe for turn ON/OFF of a 19F-MR signal) through covalent binding to the focal point of amphiphilic polymer-dendron hybrids with the labeling moiety. At the assembled micellar state, the dyes are closely packed and hence the probability for intermolecular interactions increases significantly, leading to alteration of the fluorescent properties (signal quench or shift) or the 19F-MR signal (OFF state) of the micelles. Upon enzymatic cleavage of the hydrophobic end-groups from enzyme-responsive dendron, the polymers become hydrophilic and disassemble.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: December 22, 2020
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Roey Jacob Amir, Marina Buzhor, Assaf Josef Harnoy
  • Patent number: 10842856
    Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: November 24, 2020
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: George E. Peoples, Sathibalan Ponniah
  • Patent number: 10815288
    Abstract: The present invention pertains to polynucleotides that encode CDR3 in TCR-[alpha] and TCR-[beta] chain genes of CD4+ helper T-cells that are specific to WT1 helper peptides having an amino acid sequence represented by SEQ ID NO: 123. The present invention further pertains to the peptides encoded by said polynucleotides. The present invention further pertains to CD4+ T cells into which TCR genes that contain said polynucleotides have been introduced, the induction of WT1-specific cytotoxic T-lymphocytes (CTLs) using the CD4+ T-cells, the treatment of cancer, etc.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: October 27, 2020
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventors: Haruo Sugiyama, Fumihiro Fujiki
  • Patent number: 10766930
    Abstract: An immunogenic fusion protein includes at least the following two peptides a) —on the C-terminal side, a first peptide constituted of: —the amino acid sequence of the protein S or the protein M of a human hepatitis B virus (HBV) isolate, which protein S or protein M is optionally deleted at the N-terminal end thereof, and b) —on the N-terminal side, a second peptide constituted of: —the sequence of amino acids of at least one transmembrane domain and the ectodomain of at least one protein of a Zika virus isolate selected from the envelope protein E or a fusion peptide including the envelope protein E and the protein prM.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 8, 2020
    Assignees: UNIVERSITE DE TOURS, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE—INSERM
    Inventors: Christophe Hourioux, Romuald Patient, Elodie Beaumont, Philippe Roingeard
  • Patent number: 10752669
    Abstract: The present invention pertains to polynucleotides that encode CDR3 in TCR-[alpha] and TCR-[beta] chain genes of CD4+ helper T-cells that are specific to WT1 helper peptides having an amino acid sequence represented by SEQ ID NO: 123. The present invention further pertains to the peptides encoded by said polynucleotides. The present invention further pertains to CD4+ T cells into which TCR genes that contain said polynucleotides have been introduced, the induction of WT1-specific cytotoxic T-lymphocytes (CTLs) using the CD4+ T-cells, the treatment of cancer, etc.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: August 25, 2020
    Assignee: International Institute of Cancer Immunology, Inc.
    Inventors: Haruo Sugiyama, Fumihiro Fujiki
  • Patent number: 10745466
    Abstract: This invention relates generally to molecules that specifically bind bacterial V-tip proteins of the type III secretion system of Gram negative bacteria such as PcrV from Pseudomonas aeruginosa. More specifically, this invention relates to molecules that block the injection of effector molecules into target cells. This invention also relates to molecules that specifically bind to bacterial lipoproteins, such as OprI. The molecules of the present invention are monospecific or multispecific and can bind their target antigen in a monovalent or multivalent manner. The invention also relates generally to molecules that specifically bind bacterial cell surface proteins such as OprI, and to methods of use these molecules in a variety of therapeutic, diagnostic, and/or prophylactic indications.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: August 18, 2020
    Assignee: Inhibrx, Inc.
    Inventors: Andrew Hollands, John C. Timmer, Quinn Deveraux, Brendan P. Eckelman
  • Patent number: 10669557
    Abstract: Disclosed herein are methods and compositions for targeted deletion of double-stranded DNA. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, and polynucleotides encoding same. Methods for targeted deletion include introduction of such fusion proteins, or polynucleotides encoding same, into a cell such that two targeted cleavage events occur. Subsequent cellular repair mechanisms result in deletion of sequences between the two cleavage sites.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 2, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Dmitry Guschin, Fyodor Urnov
  • Patent number: 10611801
    Abstract: The invention relates to immunogenic compositions and vaccines containing a ZIKV protein or a polynucleotide encoding a Zika virus (ZIKV) protein and uses thereof. The invention also provides methods of treating and/or preventing a ZiKV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: April 7, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan H. Barouch, Peter Abbink, Rafael Larocca
  • Patent number: 10596251
    Abstract: The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (G) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: March 24, 2020
    Assignee: NanoBio Corporation
    Inventors: Ali I. Fattom, Tarek Hamouda, Vira Bitko, James R. Baker, Jr.
  • Patent number: 10596226
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: March 24, 2020
    Assignee: The Johns Hopkins University
    Inventors: John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen
  • Patent number: 10556006
    Abstract: Disclosed herein are methods of modulation of the viability of a cell using fusion proteins comprising a transporter peptide sequence and a MYC polypeptide. Further disclosed herein are methods of modulating an immune response using the fusion proteins. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: February 11, 2020
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Curtis Turner
  • Patent number: 10550173
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Compugen, Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik
  • Patent number: 10525109
    Abstract: The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 7, 2020
    Assignee: Ansun Biopharma, Inc.
    Inventors: Fang Fang, Michael P. Malakhov
  • Patent number: 10517923
    Abstract: The present invention provides an agent, or composition containing an agent, for use in treating or preventing hypercytokinemia in a subject resulting from cytokine release from non-proliferating immune cells in blood, wherein the agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: December 31, 2019
    Assignee: Norwegian University of Science and Technology
    Inventor: Marit Otterlei
  • Patent number: 10478638
    Abstract: The present invention relates to a recombinant self-assembled protein comprising a target-oriented peptide and a use thereof The recombinant self-assembled protein according to the present invention, comprising a target-oriented peptide, does not require an additional process for providing target-orientedness, and is thus capable of delivering a desired drug to a target tissue or target cell without using additives, such as chemical binders or stabilizers; therefore, the protein can be used for photothermal therapy, drug delivery, imaging, or the like. In particular, according to the present invention, it is possible to prepare gold-protein nanoparticle fusions in which uniform high-density gold nanoparticles having target-orientedness are bound to protein surfaces, without an additional process of surface stabilization or process for providing target-orientedness.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: November 19, 2019
    Assignee: Korea University Research and Business Foundation
    Inventors: Jeewon Lee, Koo-Chul Kwon
  • Patent number: 10456475
    Abstract: Cell penetrating peptides (CPPs) are established as a strategy to move cargoes into the interior of eukaryotic cells by engaging import machinery on the cell surface. In most cases the CPP is covalently linked to the cargo; it is common to express cargo proteins with a CPP extension. In some experiments a non-specific interactions (e.g., hydrophobic interactions) have been used to form CPP-cargo complexes, but this has numerous drawbacks. Transport is less efficient and the lack of specificity means that other macromolecules in the medium will also be internalized. This application describes the use of specific CPP labeled adaptor proteins that can be used to move a wide variety of cargoes into the cell interior. The prototype adaptor protein is calmodulin; it is small, stable and easily produced, and binds short (17 amino acid) targets with high affinity in the presence of calcium. A cargo produced with a calmodulin binding tag can be internalized efficiently by CPP tagged calmodulin.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: October 29, 2019
    Assignee: Kennsaw State University Research and Service Foundation, Inc.
    Inventor: John C. Salerno
  • Patent number: 10435446
    Abstract: Coupling proteins that make strong protein-protein interactions equipped with cell penetrating peptides (CPPs) provide a convenient and powerful method to perturb cell interiors; there are many potential payloads and a broad palette of selectively membrane permeable probes. In a preferred embodiment, the coupling protein will be calmodulin or a related calcium binding protein. In a preferred embodiment, the CPP will be TAT or another CPP. In a preferred embodiment, the coupling protein will release its payload after targeting to an interior compartment. Cargo proteins can be purified by affinity methods using the same tag that allows binding by the adaptor, enabling an integrated approach with ‘gains in both function and safety. Access to cell interior compartments has potential applications in research, diagnostics, and therapeutics.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: October 8, 2019
    Inventor: John C. Salerno
  • Patent number: 10400013
    Abstract: A fusion polypeptide is disclosed, which includes: (a) a mucosa targeting polypeptide; (b) a translocating peptide for translocation; and (c) a antigenic epitope. In addition, a method for enhancing a stimulation of an immune response using the aforementioned fusion polypeptide is also disclosed.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: September 3, 2019
    Inventors: Chao-Wei Liao, Chung-Chin Chen
  • Patent number: 10364274
    Abstract: The present invention encompasses vaccines or compositions comprising the chimeric KSAC protein that possesses immunogenic and protective properties, and methods of use including administering to an animal the antigenic KSAC protein thereof to protect animals. The invention also encompasses methods for making and producing the soluble, disaggregated, refolded or active proteins from inclusion bodies produced from prokaryotes or eukaryotes.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: July 30, 2019
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEATLH USA INC.
    Inventors: Laurent Bernard Fischer, Nicolas Pierre Yves Carboulec, Fabien Lux
  • Patent number: 10351828
    Abstract: The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 16, 2019
    Assignee: Ansun Biopharma, Inc.
    Inventor: Stephen Hawley
  • Patent number: 10344075
    Abstract: T cell receptors (TCRs) that have specificity for the WT1 antigen are provided. The TCRs include higher affinity TCRs that were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 9, 2019
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Sheena N. Smith, Daniel T. Harris, David M. Kranz, Philip D. Greenberg, Thomas M. Schmitt
  • Patent number: 10329323
    Abstract: Disclosed here includes a method for purifying a biologic composition, comprising diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method disclosed here can be particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris).
    Type: Grant
    Filed: July 25, 2015
    Date of Patent: June 25, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, United Therapeutics Corporation
    Inventors: Samir H. Shaban, Mary P. Koleck, David A. Meh, Gerald M. Farquharson, Timothy O. Atolagbe, George Mitra
  • Patent number: 10287572
    Abstract: This disclosure describes non-naturally occurring protein scaffolds and methods of making and using the protein scaffolds. In one aspect, therefore, this disclosure describes a non-naturally occurring protein scaffold that includes a plurality of structural domains and a plurality of loop regions that include an amino acid sequence that varies from a naturally-occurring loop region by at least one amino acid deletion, substitution, or addition. Generally, the structural domain or domains can include at least one ? structure and/or at least one a helix.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: May 14, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Benjamin Joseph Hackel, Max Anthony Kruziki, Sumit Bhatnagar, Hong Zhou
  • Patent number: 10253069
    Abstract: The present invention provides compositions and methods for regulating arterial tone based on the discovery herein of novel expression and regulation of hemoglobin alpha and cytochrome B5 reductase 3 and the effects on NO and NOS.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: April 9, 2019
    Assignee: University of Virginia Patent Foundation
    Inventors: Benjamin M. Gaston, Adam C. Straub, Brant E. Isakson, Linda Columbus
  • Patent number: 10251990
    Abstract: A method for automated processing of a cellular product comprising target substrate cells, the method comprising providing a separation apparatus configured to associate with a disposable sterile circuit comprising a separator in communication with the cellular product.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: April 9, 2019
    Assignee: Fenwal, Inc.
    Inventors: Christopher J. Wegener, Bret M. Olson, Alaina Schlinker, Steven Binninger, Avnie A. Kadakia
  • Patent number: 10201601
    Abstract: The present invention relates to the microbial immunogens engineered to bear ?-gal epitope(s) for induction of potent humoral and cellular immune responses when administered to subjects having anti-Gal antibodies. In one embodiment, the present invention provides compositions and methods for propagating influenza virus in human, ape, Old World monkey or bird cells that have been engineered to express an ?1,3galactosyltransferase (? 1,3GT) gene to produce virions bearing hemagglutinin molecules containing ?-gal epitopes, to increase the immunogenicity of the influenza virus. In another embodiment, the present invention provides fusion proteins between influenza virus hemagglutinin and a microbial peptide or protein of interest, and enzymatic processing of this fusion protein to carry ?-gal epitopes, to increase the immunogenicity of the microbial peptide or protein of interest.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: February 12, 2019
    Assignee: University of Massachusetts
    Inventor: Uri Galili
  • Patent number: 10189885
    Abstract: The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: January 29, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yvonne Paterson, Paulo Maciag
  • Patent number: 10149898
    Abstract: Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: December 11, 2018
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian C. Turner, Gregory Alan Bird
  • Patent number: 10138205
    Abstract: The disclosure relates to the field of fusion proteins. In some aspects, the invention relates to artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes and uses thereof. In some aspects, the disclosure relates to compounds produced by artificial cytochrome P450 enzymes.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: November 27, 2018
    Assignee: University of Florida Research Foundation, Incorporated
    Inventor: Yousong Ding
  • Patent number: 10138279
    Abstract: The present invention relates to methods and compositions for stimulating an immune response. Specifically, the present invention provides methods of inducing an immune response to bacteria of the genus Bacillus (e.g., Bacillus anthracis) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising Bacillus anthracis or an immunogenic portion thereof). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination) and research applications.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: November 27, 2018
    Assignee: Regents of the University of Michigan
    Inventors: James R. Baker, Jr., Anna Bielinska, Andrzej Myc
  • Patent number: 10124054
    Abstract: Provided is a vaccine combination against multiple dengue virus serotypes and preparation thereof. The vaccine combination includes a first vaccine and a second vaccine, wherein the first vaccine includes a live-attenuated dengue virus and a live-attenuated chimeric dengue virus, and the second vaccine includes a plurality type of recombinant flagellin and envelope domain III fusion proteins, wherein an envelope domain III of each type of the recombinant flagellin and envelope domain III fusion proteins is derived from a different dengue virus serotype. Also provided is a method of preventing or treating viral infection by multiple dengue virus serotypes in a subject using the vaccine combination, including the steps of administering the first and then the second vaccines at a time interval of about 1-5 weeks.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: November 13, 2018
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Suh-Chin Wu, Hsiao-Han Lin, Meng-Ju Tsai, Guan-Cheng Lin
  • Patent number: 10076564
    Abstract: The invention relates to the use of a bacterial artificial chromosome (BAC) for the preparation of a vaccine, wherein the BAC comprises an inducible bacterial ori sequence for amplification of the BAC to more than 10 copies per bacterial cell. Plus a viral expression cassette comprising a cDNA of an attenuated RNA virus genome and comprising cis-regulatory elements for transcription of said viral cDNA in mammalian cells and for processing of the transcribed RNA into infectious viral RNA.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: September 18, 2018
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Kai Dallmeier, Johan Neyts
  • Patent number: 10030060
    Abstract: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 24, 2018
    Assignee: OPKO Biologics Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Patent number: 9951119
    Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 24, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 9908921
    Abstract: The present invention provides galectin-9 variant having substantially the same bioactivity as in wild-type galectin-9 and being superior in protease stability, solubility, and yield. The galectin-9 variant according to the present invention is a protein including the following NCRD and the following CCRD composed of an N-terminal region and a C-terminal region. The C terminus of the NCRD and the N terminus of the CCRD are directly or indirectly bound to each other. The NCRD is (N1) a peptide composed of an amino acid sequence represented by SEQ ID NO: 1. The N-terminal region of the CCRD is (C-N1) a peptide composed of an amino acid sequence obtained by deletion of 1 to 17 amino acids in an amino acid sequence represented by SEQ ID NO: 3. The C-terminal region is (C-C1) a peptide composed of an amino acid sequence represented by SEQ ID NO: 5.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: March 6, 2018
    Assignee: National University Corporation Kagawa University
    Inventors: Nozomu Nishi, Aiko Itoh
  • Patent number: 9901635
    Abstract: The present invention relates to therapeutic compounds, such as vaccines against human papillomavirus (HPV) and in particular to DNA vaccines against HPV16 or HPV18. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment of various HPV induced diseases, such as cancers and infectious diseases by application.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 27, 2018
    Assignee: Vaccibody AS
    Inventors: Ole Henrik Brekke, Agnete Brunsvik Fredriksen, Ali Areffard, Mona Mari Lindeberg
  • Patent number: 9889189
    Abstract: Disclosed are universal influenza A vaccines capable of providing broader crossprotection. The vaccine contains a fusion protein comprising tandem repeats of heterologous M2e epitope sequences that have been molecularly and genetically designed to provide broad cross-protection. The fusion protein may be incorporated into virus-like particles (VLPs) or a replicating live attenuated influenza virus vaccine, and administered alone or in combination with other influenza vaccines.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: February 13, 2018
    Assignee: Georgia State University Research Foundation
    Inventors: Sang-Moo Kang, Min-Chul Kim
  • Patent number: RE48863
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 28, 2021
    Assignee: Wyeth LLC
    Inventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint